Harrow, Inc. Cash and Restricted Cash
Harrow, Inc. (HROW) had Cash and Restricted Cash of $72.60 million as of 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2024-11-14
- 2024-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $72.60M.
- 2024-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $70.97M.
- 2023-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $74.08M.
- 2023-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $65.61M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2024-09-30 | $72.60M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $70.97M 10-Q · filed 2024-08-07 | |
| 2023-12-31 | $74.08M 10-Q · filed 2024-11-14 | |
| 2023-09-30 | $65.61M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $22.75M 10-Q · filed 2024-08-07 | |
| 2023-03-31 | $19.25M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $96.27M 10-Q · filed 2024-11-14 | |
| 2022-09-30 | $44.96M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $46.44M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $41.95M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $42.17M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $57.86M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $72.85M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $6.50M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $4.30M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $5.73M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $4.10M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $4.12M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $4.95M 10-K · filed 2021-03-08 | |
| 2019-09-30 | $3.63M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $4.19M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $4.26M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $6.84M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $6.32M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $4.17M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $2.89M 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $4.22M 10-Q · filed 2019-05-09 | |
| 2017-09-30 | $4.07M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $4.37M 10-Q · filed 2018-08-06 | |
| 2017-03-31 | $7.40M 10-Q · filed 2018-05-15 | |
| 2016-12-31 | $9.05M 10-K · filed 2019-03-12 | $8.85M 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |